Abstract 341P
Background
Lean body mass and low muscle mass are associated with survival, quality of life (QOL), and tolerance to treatment in cancer patients. Most early breast cancer patients were reported in overweight and obese nutrition status. There is still limited data evaluating the relationship between muscle mass and QOL in breast cancer patients, especially in early stages. The aim of this study is to examine the relationship between muscle mass and QOL domain in breast cancer patients before underwent chemotherapy.
Methods
A total of 80 breast cancer patients were enrolled in this study. Women breast cancer patients before they underwent chemotherapy were included in this study. Skeletal muscle mass was measured by bioelectrical impedance analysis, and it was reported as the Skeletal Muscle Index (SMI). QoL was assessed using the EORTC-QLQ-C30. The correlation between SMI and QOL was evaluated using Pearson or Spearmen correlation test based on the normality data.
Results
The mean of age was 47.39+7.07 years old. The median of body mass index (BMI) was 23.15(7.86-47.26) kg/m2. The distribution of BMI for underweight, normo-weight, overweight and obese were 5(6.3%); 33(41.3%); 16(21.1%); and 26(32.6%), respectively. Most patients were in early breast cancer 71 of 80 (88.8%). The median of SMI was 5.72(1.91-12.35). The median of QOL global health status, physical function, role function, emotional function, cognitive function, and social function domain were 66.67(0-100); 93.33(0-133.33); 100(0-133.33); 83.33(33.33-100); 100(16.67-100); and 100(0-100), respectively. The correlation between SMI and QOL global health status, physical function, role function, emotional function, cognitive function, and social function domain were (r 0.194, p 0.085); (r 0.021, p 0.851); (r 0.009, p 0.939); (r 0.061, p 0.588); (r 0.280, p 0.012); and (r 0.078, p 0.490), respectively.
Conclusions
Almost all QOL domains of breast cancer patients before underwent chemotherapy showed good results. The relationship between muscle mass and QOL in breast cancer patients before underwent chemotherapy only showed in the cognitive domain. Further studies need to be done to evaluate the physical activity and protein consumption practice with QoL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Real world outcomes in elderly women with HER2-positive advanced breast cancer
Presenter: Nicole Evans
Session: e-Poster Display Session
52P - Chemotherapy selection in routine clinical practice in Japan for HER2-negative advanced or metastatic breast cancer (KBCRN A001: E-SPEC Study)
Presenter: Yookija Kang
Session: e-Poster Display Session
53P - Aromatase inhibitor and cyclin-dependent kinase 4/6 inhibitor treated HR+/HER2- metastatic breast cancer differ to those treated with Aromatase inhibitors alone on progression
Presenter: Indunil Weerasena
Session: e-Poster Display Session
54P - Platinum-based chemotherapy in advanced breast cancer (ABC): Real-world outcome from a tertiary cancer centre in India
Presenter: Indhuja Vijesh
Session: e-Poster Display Session
55P - Eribulin in heavily pretreated metastatic breast cancer: A real-world data from India
Presenter: Tanmoy Mandal
Session: e-Poster Display Session
56P - Treatment of palbociclib in hormone receptor-positive breast cancer in China: A real-world study
Presenter: Yiqi Yang
Session: e-Poster Display Session
57P - Therapeutic vulnerability of malignant phyllodes tumour to pazopanib identified through a novel patient-derived xenograft and cell line model
Presenter: Dave Ng
Session: e-Poster Display Session
58P - Survival benefit of local treatments in breast cancer with lung metastasis: Results from a large retrospective study
Presenter: Yimeng Chen
Session: e-Poster Display Session
59P - The impact of site of metastasis on overall survival in indigenous and non-indigenous patients of Western Australia with breast cancer
Presenter: Azim Khan
Session: e-Poster Display Session
60P - Risk factors of bone metastasis and skeletal-related events in high-risk breast cancer patients
Presenter: Sumadi Lukman Anwar
Session: e-Poster Display Session